A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Completed · Phase 2 · Has a placebo group

Conditions studied: Psoriasis

In brief

This multicenter study is being conducted to provide additional PF-06826647 safety and tolerability data, and to further explore the clinical efficacy of PF-06826647 in the treatment of moderate to severe plaque psoriasis. Additionally, the study is intended to enable selection of oral dose and dosing regimen for the future clinical development of PF-06826647.

Key facts

Study ID

NCT03895372

Run by

Pfizer

People needed

179

Starts

2019-06-27

Expected to finish

2020-11-26

Last updated by the study team

2021-08-27

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female between the ages of 18 and 75 years.
• Participants with a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months.
• Have a PASI score of 12 or greater AND a Physician Global Assessment score of 3 (moderate) or 4 (severe).
• Have plaque-type psoriasis covering at least 10 % of total body surface area (BSA).

You may not qualify if…

• Have non-plaque forms of psoriasis.
• Drug-induced psoriasis.
• Current active infection.
• Infected with Mycobacterium tuberculosis (TB).
• Have any history of malignancies.
• Require treatment with prohibited concomitant medications(s).
• Positive for hepatitis B or C, or human immunodeficiency virus (HIV).

Where it is running

• Alliance Dermatology and Mohs Center — Phoenix, Arizona, United States
• Center for Dermatology and Plastic Surgery/CCT — Scottsdale, Arizona, United States
• Center for Dermatology and Plastic Surgery — Scottsdale, Arizona, United States
• Anaheim Clinical Trials, LLC — Anaheim, California, United States
• Kern Research. Inc. — Bakersfield, California, United States
• California Dermatology & Clinical Research Institute — Encinitas, California, United States
• Imaging Healthcare Specialists — San Diego, California, United States
• Medderm Associates Dermatology — San Diego, California, United States
• University Clinical Trials — San Diego, California, United States
• Renstar Medical Research — Ocala, Florida, United States
• MidState Skin Institute — Ocala, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• Advanced Diagnostic Group — Orange Park, Florida, United States
• Park Avenue Dermatology — Orange Park, Florida, United States
• Leavitt Medical Associates of Florida d/b/a Ameriderm Research — Ormond Beach, Florida, United States
• ForCare Clinical Research — Tampa, Florida, United States
• Hamilton Research, LLC — Alpharetta, Georgia, United States
• Epiphany Dermatology of Kansas, LLC — Overland Park, Kansas, United States
• Qualmedica Research, LLC — Owensboro, Kentucky, United States
• Owensboro Dermatology Associates — Owensboro, Kentucky, United States
• DelRicht Research — Baton Rouge, Louisiana, United States
• DelRicht Research — Baton Rouge, Louisiana, United States
• Vital Prospects Clinical Research Institute, PC — Tulsa, Oklahoma, United States
• Arlington Research Center, Inc. — Arlington, Texas, United States
• Wiseman Dermatology Research Inc. — Winnipeg, Manitoba, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.